Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
Phase 2
Terminated
Conditions
Graft Versus Host Disease
Interventions
Drug: Fludarabine
Drug: Clofarabine
Radiation: Full body irradiation
Drug: Cyclophosphamide
Other: stem cell transplantation
Other: nuclear cells
Drug: Thymoglobulin Injectable Product
Subscribe
First Posted Date
2017-08-28
Last Posted Date
2022-07-15
Lead Sponsor
Nantes University Hospital
Target Recruit Count
47
Registration Number
NCT03263767
Locations
🇫🇷
Nantes Uh, Nantes, France
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy